Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1170

Sort by

Sort Order Select

Journal Articles

OBF1 and OCT1/2 regulate the germinal center B-cell program

Ralf Küppers

Blood (2021) 137 (21): 2862–2863.

https://doi.org/10.1182/blood.2021010689

Published: 2021

Journal Articles

OBF1 and Oct factors control the germinal center transcriptional program

Shuang Song, Chun Cao, Mohamed-Amin Choukrallah, Fengyuan Tang, Gerhard Christofori, Hubertus Kohler, Fabian Wu, Barna D. Fodor, Mathias Frederiksen, Simon N. Willis, Jacob T. Jackson, Stephen L. Nutt, Stefan Dirnhofer, Michael B. Stadler, Patrick Matthias

Blood (2021) 137 (21): 2920–2934.

https://doi.org/10.1182/blood.2020010175

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

Yongxia Wu, PhD MD, Mengmeng Zhang, MD, David Bastian, Mohammed Hanief Sofi, PhD MS, Steven Douglas Schutt, BS, Hee-Jin Choi, PhD, Corey Mealer, Hung D Nguyen, PhD, Linlu Tian, Xue-Zhong Yu, MD MS

Blood (2019) 134 (Supplement_1): 623.

https://doi.org/10.1182/blood-2019-131587

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations

Blood (2019) 134 (Supplement_1): 684.

https://doi.org/10.1182/blood-2019-127673

Published: 2019

Journal Articles

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Miguel Quintela, Iolanda Vieira, Cláudia Moreira, Sérgio Chacim, Nelson Domingues, Isabel Oliveira, Ana Espirito Santo, Maria Ilidia Moreira, Ângelo Martins, Maria Luisa Viterbo, Dulcineia Pereira, Jose Mario Mariz

Blood (2019) 134 (Supplement_1): 5356.

https://doi.org/10.1182/blood-2019-131254

Published: 2019

Journal Articles

High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

Blood (2019) 134 (Supplement_1): 1484.

https://doi.org/10.1182/blood-2019-129832

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

Palmitoylation of GNA13 Is Essential for Its Tumor Suppressor Function and Its Inhibition Confers Hypersensitivity of B-Cell Lymphoma to BCL2 Inhibitors

Zhizhou Xia, Xiuli Zhang, Ping Liu, MD PhD, Bo Jiao, PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3787.

https://doi.org/10.1182/blood-2019-126368

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL

Raoul Santiago, MDMSc, Nathalie Johnson, MD, Svetlana Dmitrienko, MD PhD, Andreas Papadakis, PhD, Naciba Benlimame, PhD, François Mercier, MD, Koren Kathleen Mann, PhD, Sarit Assouline, MD

Blood (2019) 134 (Supplement_1): 3968.

https://doi.org/10.1182/blood-2019-122207

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Charline Moulin, Romain Morizot, Thomas Remen, Hélène Augé, Florian Bouclet, Marion Divoux, Sandra Lomazzi, Caroline Dartigeas, MD, Anne Quinquenel, MD, Hélène Busby, MD, Cecile Tomowiak, Veronique Leblond, MD PhD, Catherine Thieblemont, MD PhD, Florence Cymbalista, MD PhD, Marie C Bene, PharmD,DPhil, Romain Guièze, MD PhD, Julien Broseus, MD PhD, Pierre Feugier, MD PhD

Blood (2019) 134 (Supplement_1): 4112.

https://doi.org/10.1182/blood-2019-128053

Published: 2019

Journal Articles

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

Anna Dodero, MD, Anna Guidetti, MD, Fabrizio Marino, MD, Cristiana Carniti, PhD, Stefania Banfi, Alessandra Tucci, MD, Monica Balzarotti, Antonello Domenico Cabras, MD, Valentina Monti, PhD, Liliana Franca Devizzi, MD, Lucia Farina, MD, Maria Chiara Di Chio, MD, Giuseppe Rossi, Carmelo Carlo-Stella, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 4116.

https://doi.org/10.1182/blood-2019-124350

Published: 2019

Journal Articles

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Peiqi Zhao, Huilai Zhang, MD, Kai Fu, MD PhD, Xianhuo Wang, MD, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou

Blood (2019) 134 (Supplement_1): 4117.

https://doi.org/10.1182/blood-2019-127666

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

Induction of Activated T Follicular Helper Cells Is Critical for Anti-FVIII Inhibitor Development in Hemophilia a Mice

Weiqing Jing, MD PhD, Juan Chen, PhD, Yuanhua Cai, MD, Yingyu Chen, PhD, Jocelyn A. Schroeder, Weiguo Cui, MD PhD, Qizhen Shi, MD PhD

Blood (2019) 134 (Supplement_1): 92.

https://doi.org/10.1182/blood-2019-123777

Published: 2019

Journal Articles

Cell of Origin (COO) Association with High Body Mass Index (BMI) and Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Kathleen Maignan, NP, MSN, Shaked Peleg Azzam, MA, Blythe Adamson, PhD MPH, Christina M. Parrinello, PhD MPH, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 4123.

https://doi.org/10.1182/blood-2019-129470

Published: 2019

Journal Articles

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Jari Haukka, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 2781.

https://doi.org/10.1182/blood-2019-131220

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

OBF1 and OCT1/2 regulate the germinal center B-cell program

OBF1 and Oct factors control the germinal center transcriptional program

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Palmitoylation of GNA13 Is Essential for Its Tumor Suppressor Function and Its Inhibition Confers Hypersensitivity of B-Cell Lymphoma to BCL2 Inhibitors

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Induction of Activated T Follicular Helper Cells Is Critical for Anti-FVIII Inhibitor Development in Hemophilia a Mice

Cell of Origin (COO) Association with High Body Mass Index (BMI) and Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only